US 12,378,552 B2
Oligomeric compound for inhibiting expression of factor XI
Dmitry Samarsky, Gaithersburg, MD (US)
Assigned to Sirnaomics, Inc., Germantown, MD (US)
Filed by Sirnaomics, Inc., Gatithersburg, MD (US)
Filed on Apr. 13, 2022, as Appl. No. 17/720,129.
Claims priority of provisional application 63/253,040, filed on Oct. 6, 2021.
Claims priority of provisional application 63/174,533, filed on Apr. 13, 2021.
Prior Publication US 2022/0364087 A1, Nov. 17, 2022
Int. Cl. C12N 15/113 (2010.01); A61K 38/36 (2006.01); A61P 7/02 (2006.01); C12N 9/64 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 38/36 (2013.01); A61P 7/02 (2018.01); C12N 9/6443 (2013.01); C12N 2310/11 (2013.01); C12Y 304/21027 (2013.01)] 20 Claims
OG exemplary drawing
 
1. An oligomeric compound that inhibits expression of Factor XI (“FXI”), comprising a single oligonucleotide strand, wherein said single strand consists of a modified or unmodified oligonucleotide selected from the group consisting of SEQ ID NOs: 2252, 2287, 2288, 2290-2292, 2297, 2300, 2303, 2306, 2309, 2312, 2315, 2321, 2324, 2327, 2332, 2334-2336, 2338, 2339, 2343, 2348, 2351, 2352, 2354, 2355, and 2357-2366.